Academic Journal
Pre-analytical standardization and multi-biofluid harmonization for liquid biopsy biomarkers in lung cancer: From discovery to clinical laboratory implementation.
| Τίτλος: | Pre-analytical standardization and multi-biofluid harmonization for liquid biopsy biomarkers in lung cancer: From discovery to clinical laboratory implementation. |
|---|---|
| Συγγραφείς: | Sharapov S; Samarkand State Medical University, Samarkand 140100, Uzbekistan., Tolibov M; Samarkand State Medical University, Samarkand 140100, Uzbekistan., Khamidova F; Samarkand State Medical University, Samarkand 140100, Uzbekistan., Akhmedova S; Tashkent State Medical University, Tashkent 100109, Uzbekistan., Khasanov S; Samarkand State University named after Sharof Rashidov, Samarkand 140104, Uzbekistan. Electronic address: shakhbozkhasanov93@gmail.com., Yusufova M; Tashkent State Medical University, Tashkent 100109, Uzbekistan., Azizov B; Tashkent State Medical University, Tashkent 100109, Uzbekistan., Dustova N; Bukhara State Medical Institute named after Abu Ali ibn Sino, Bukhara 200126, Uzbekistan., Yokubova M; Andijan State Medical Institute, Andijan 170119, Uzbekistan. |
| Πηγή: | Clinica chimica acta; international journal of clinical chemistry [Clin Chim Acta] 2026 Aug 15; Vol. 590, pp. 121097. Date of Electronic Publication: 2026 May 19. |
| Τύπος έκδοσης: | Journal Article; Review |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 1302422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-3492 (Electronic) Linking ISSN: 00098981 NLM ISO Abbreviation: Clin Chim Acta Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Amsterdam, Elsevier. |
| Ιατρικοί όροι (MeSH): | Lung Neoplasms*/diagnosis , Lung Neoplasms*/metabolism , Lung Neoplasms*/pathology , Biomarkers, Tumor*/analysis , Body Fluids*/chemistry , Laboratories, Clinical*/standards, Liquid Biopsy/standards ; Humans ; Reference Standards |
| Περίληψη: | Lung cancer remains the leading cause of cancer-related mortality worldwide, with early detection being critical for improving survival outcomes. Liquid biopsy using circulating biomarkers from blood, urine, saliva, sputum, exhaled breath condensate (EBC), and sweat has emerged as a promising non-invasive approach for lung cancer diagnosis, prognosis, and treatment monitoring. However, despite an abundance of biomarker discovery studies, clinical translation has been critically hampered by the absence of standardized pre-analytical protocols, inter-platform analytical discordance, and a lack of systematic frameworks for integrating biomarkers across multiple biofluids. This review identifies and addresses a major unmet need in the field: the harmonization of pre-analytical, analytical, and post-analytical workflows across diverse non-invasive biofluids for lung cancer liquid biopsy. We systematically evaluate pre-analytical variables specific to each biofluid, including collection methods, processing timelines, storage conditions, and matrix-specific confounders such as hemolysis, salivary contamination, and volatile compound degradation. We compare analytical platforms, including qRT-PCR, next-generation sequencing, mass spectrometry, ELISA, and electrochemical biosensors, and assess their cross-platform reproducibility for key analyte classes: circulating tumor DNA, microRNAs, proteins, metabolites, volatile organic compounds, and extracellular vesicles. Furthermore, we propose a structured clinical implementation roadmap encompassing external quality assessment schemes, commutable reference materials, multi-center validation requirements, and regulatory considerations. We conclude that the integration of multi-biofluid biomarker panels with artificial intelligence-assisted interpretation, combined with rigorous pre-analytical standardization, holds the greatest promise for translating liquid biopsy from bench to bedside in lung cancer care. (Copyright © 2026 Elsevier B.V. All rights reserved.) |
| Competing Interests: | Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. |
| Contributed Indexing: | Keywords: Biomarker harmonization; Clinical implementation; Liquid biopsy; Lung cancer; Multi-biofluid integration; Non-invasive diagnostics; Pre-analytical standardization; Quality assurance |
| Substance Nomenclature: | 0 (Biomarkers, Tumor) |
| Entry Date(s): | Date Created: 20260520 Date Completed: 20260710 Latest Revision: 20260710 |
| Update Code: | 20260711 |
| DOI: | 10.1016/j.cca.2026.121097 |
| PMID: | 42162904 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1873-3492 |
|---|---|
| DOI: | 10.1016/j.cca.2026.121097 |